FDA
-
-
-
-
-
-
-
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
-
-
-
-
-
-
-
Orchestra BioMed publishes clinical data on blood pressure therapy
-
-
-
-
-
-
-
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
-
-
-
-
-
-
-
Ligand and Medtronic invest $70 million in Orchestra BioMed
-
-
-
-
-
-
-
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloo
-
-
-
-
-
-
-
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Orchestra BioMed (OBIO) Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy f
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

